Worth reading
44Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Deterioration
Direction inferred from the company’s description.Scale
-44.9
% (year-on-year change in operating income)Wording
Conditional
How definitive the wording is.Results for this period
Third quarter1 June 2025–28 February 2026ConsolidatedJapanese GAAPNet Sales46,888¥ millionYear on year -1.4%Progress 69.3%
Operating profit393¥ millionYear on year -44.9%Progress 66.6%
Ordinary income486¥ millionYear on year -36.0%Progress 76.9%
Net income attributable to owners of the parent441¥ millionYear on year -4.3%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥175.71
Financial position at period-end
Total assets25,498¥ million
of which net assets 8,880 ¥ millionEquity ratio 34.8%vs. prior year-end +2.2pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenueMedical device sales ¥46,677 million (YoY -1.3%), Medical Equipment Manufacturing and Sales ¥156 million (YoY -8.2%), Medical Mall Business ¥54 million (YoY +2.3%)
Segment profitMedical device sales ¥1,327 million (YoY -17.8%), Medical Equipment Manufacturing and Sales ¥-144 million, Medical Mall Business ¥6 million (YoY +258.1%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥67,647 million (YoY +4.9%)
Operating profit¥590 million (YoY -29.6%)
Ordinary income¥632 million (YoY -30.5%)
Profit attributable to owners of the parent¥354 million (YoY -42.6%)
Net income per share¥143.58
Annual Dividend Forecast¥75 → ¥70
Factors Behind Changes in Business Performance
In the medical equipment sales business, demand for consumable medical equipment, including medical supplies, increased as the number of examinations and surgeries rose. However, demand for capital investment by medical institutions decreased from the same period of the previous year, resulting in lower net sales. Profit declined as operating income was affected by the decrease in gross profit resulting from lower sales and an increase in selling, general and administrative expenses, including personnel expenses.
Disclosure regarding the going concern assumption
No applicable matters
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed / Exclusions not constituting material changes Number of companies 1 / Company name 株式会社イーディライト / Timing Effective 31 October 2025, from the second quarter of the consolidated fiscal period
Breakdown of extraordinary income (loss)Extraordinary income Reversal of allowance for doubtful accounts ¥50 million, Gain on revision of retirement benefit plans ¥13 million / Extraordinary loss Loss on sale of shares in a subsidiary ¥2 million
Depreciation and amortization¥152 million
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingWhether applicable No / Subject person Not disclosed
Issued Shares at Period-End2,553,000
Treasury Shares at Period-End62,107
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 June 2025–28 February 2026 |
| Net Sales | ¥46,888 million (YoY -1.4%) |
| Operating profit | ¥393 million (YoY -44.9%) |
| Ordinary income | ¥486 million (YoY -36.0%) |
| Profit attributable to owners of the parent | ¥441 million (YoY -4.3%) |
| Net income per share | ¥175.71 |
| Equity ratio | End of the current fiscal period 34.8 / End of previous period 32.6 |
| Total assets | ¥25,498 million |
| Net assets | ¥8,880 million |
| Full-year earnings forecast | Net Sales ¥67,647 million (YoY +4.9%) / Operating profit ¥590 million (YoY -29.6%) / Ordinary income ¥632 million (YoY -30.5%) / Profit attributable to owners of the parent ¥354 million (YoY -42.6%) / Net income per share ¥143.58 |
| Annual Dividend Forecast | ¥75 → ¥70 |
| Segment revenue | Medical device sales ¥46,677 million (YoY -1.3%), Medical Equipment Manufacturing and Sales ¥156 million (YoY -8.2%), Medical Mall Business ¥54 million (YoY +2.3%) |
| Segment profit | Medical device sales ¥1,327 million (YoY -17.8%), Medical Equipment Manufacturing and Sales ¥-144 million, Medical Mall Business ¥6 million (YoY +258.1%) |
| Depreciation and amortization | ¥152 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Reversal of allowance for doubtful accounts ¥50 million, Gain on revision of retirement benefit plans ¥13 million / Extraordinary loss Loss on sale of shares in a subsidiary ¥2 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed / Exclusions not constituting material changes Number of companies 1 / Company name 株式会社イーディライト / Timing Effective 31 October 2025, from the second quarter of the consolidated fiscal period |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 2,553,000 |
| Treasury Shares at Period-End | 62,107 |
| Factors Behind Changes in Business Performance | In the medical equipment sales business, demand for consumable medical equipment, including medical supplies, increased as the number of examinations and surgeries rose. However, demand for capital investment by medical institutions decreased from the same period of the previous year, resulting in lower net sales. Profit declined as operating income was affected by the decrease in gross profit resulting from lower sales and an increase in selling, general and administrative expenses, including personnel expenses. |
Items this document does not state (12)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodRevision to Earnings ForecastPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogImpairment lossMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Net sales declined as demand for capital investment by medical institutions decreased from the same period of the previous year. Operating income declined due to the resulting decrease in gross profit and an increase in selling, general and administrative expenses, including personnel expenses.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.